**SECTION D: KEY REVIEWS & OVERVIEWS**\
\
STUDY_ID,FIRST_AUTHOR,YEAR,JOURNAL,ARTICLE_TYPE,POPULATION_FOCUS,IIH_SEVERITY_FOCUS,TOPIC_CATEGORY,STATEMENT_ID,STATEMENT_TYPE,INTERVENTION_OR_FACTOR,OUTCOME_CATEGORY,MECHANISM_OR_CONCEPT_TAGS,SUMMARY_STATEMENT_TEXT,EVIDENCE_LEVEL_AS_REPORTED,REFERS_TO_PRIMARY_TRIALS,KEY_REFERENCED_TRIALS_TEXT,RELEVANCE_FOR_CAI_INTENSITY_MODEL_TEXT,PDF_SOURCE_IDENTIFIER

Mollan_2018_JNNP,Mollan,2018,J Neurol Neurosurg
Psychiatry,ConsensusGuideline,Adults,general_IIH,Management,S01,TreatmentRecommendation,Acetazolamide;WeightLoss,VisualFunction;Headache,CAI;FirstLine,Consensus
guidance recommends acetazolamide and weight loss as first-line
therapy.,ExpertOpinion,Yes,IIHTT (Wall 2014); Ball 2011,Supports ACZ as
first-line standard of care.,10.1136/jnnp-2017-317440.pdf

Mollan_2018_JNNP,Mollan,2018,J Neurol Neurosurg
Psychiatry,ConsensusGuideline,Adults,general_IIH,Management,S02,DosingRecommendation,Acetazolamide,ICP;Headache,CAI;Dosing,A
popular starting dose of acetazolamide is 250-500 mg twice a day,
titrating up.,ExpertOpinion,No,NR,Provides standard dosing/titration
algorithm.,10.1136/jnnp-2017-317440.pdf

Mollan_2018_JNNP,Mollan,2018,J Neurol Neurosurg
Psychiatry,ConsensusGuideline,Adults,mild_visual_loss,Management,S03,DosingRecommendation,Acetazolamide,VisualFunction,CAI;Dosing;IIHTT,The
IIHTT used a maximal dose of 4g daily.,NR,Yes,IIHTT (Wall 2014),Defines
upper limit/target dose in trials.,10.1136/jnnp-2017-317440.pdf

Mollan_2018_JNNP,Mollan,2018,J Neurol Neurosurg
Psychiatry,ConsensusGuideline,Adults,general_IIH,Management,S04,TreatmentRecommendation,Topiramate,ICP;Weight,CAI;WeightLoss,Topiramate
has carbonic anhydrase activity and can suppress appetite; used as
alternative.,NR,Yes,Celebisoy 2007,Links TPM to CAI and weight loss
mechanisms.,10.1136/jnnp-2017-317440.pdf

Mollan_2018_JNNP,Mollan,2018,J Neurol Neurosurg
Psychiatry,ConsensusGuideline,Adults,general_IIH,Management,S05,TreatmentRecommendation,WeightLoss,ICP;Papilledema;Headache,Obesity;DiseaseModification,Weight
loss is the only disease-modifying therapy in typical
IIH.,High,Yes,Sinclair 2010,Establishes weight loss as primary disease
modifier.,10.1136/jnnp-2017-317440.pdf

Mollan_2018_JNNP,Mollan,2018,J Neurol Neurosurg
Psychiatry,ConsensusGuideline,Adults,general_IIH,Management,S06,TreatmentRecommendation,WeightLoss,Remission,Obesity;Threshold,\"Up
to 15% weight loss was required to put IIH into remission in one
cohort.\",NR,Yes,Sinclair 2010,Provides a potential target threshold for
weight loss.,10.1136/jnnp-2017-317440.pdf

Mollan_2018_JNNP,Mollan,2018,J Neurol Neurosurg
Psychiatry,ConsensusGuideline,Adults,general_IIH,Mechanisms,S07,Mechanism,VenousSinusStenosis,ICP,VenousOutflow;CauseVsConsequence,Stenosis
may result from intrinsic anatomy or extrinsic compression by increased
ICP.,NR,No,NR,Highlights the VSS \'chicken-or-egg\'
debate.,10.1136/jnnp-2017-317440.pdf

Mollan_2018_JNNP,Mollan,2018,J Neurol Neurosurg
Psychiatry,ConsensusGuideline,Adults,general_IIH,Management,S08,SurgicalRecommendation,VenousSinusStenting,ICP,\"The
role of neurovascular stenting in IIH is not yet
established.\",ExpertOpinion,No,NR,Classifies VSS as
experimental/uncertain.,10.1136/jnnp-2017-317440.pdf

Mollan_2018_JNNP,Mollan,2018,J Neurol Neurosurg
Psychiatry,ConsensusGuideline,Adults,general_IIH,Management,S09,TreatmentRecommendation,LumbarPuncture,ICP;Headache,CSFManagement,Serial
lumbar punctures are not recommended for management of
IIH.,ExpertOpinion,No,NR,Discourages serial LPs as primary
treatment.,10.1136/jnnp-2017-317440.pdf

Mollan_2018_JNNP,Mollan,2018,J Neurol Neurosurg
Psychiatry,ConsensusGuideline,Adults,general_IIH,Management,S10,MonitoringRecommendation,VenousSinusStenosis,Diagnosis,VenousOutflow;CVST,CT
or MR venography is mandatory to exclude cerebral sinus
thrombosis.,High,No,NR,Defines VSS/CVST as a key diagnostic
exclusion.,10.1136/jnnp-2017-317440.pdf

Mollan_2018_JNNP,Mollan,2018,J Neurol Neurosurg
Psychiatry,ConsensusGuideline,Adults,general_IIH,Management,S11,MonitoringRecommendation,LumbarPuncture,ICP,Diagnosis;CSFPressure,Diagnostic
criteria mandate a cut-off opening pressure of \>25 cm
CSF.,High,Yes,Friedman 2013,Defines the ICP threshold for
diagnosis.,10.1136/jnnp-2017-317440.pdf

Mollan_2018_JNNP,Mollan,2018,J Neurol Neurosurg
Psychiatry,ConsensusGuideline,Adults,fulminant,Management,S12,SurgicalRecommendation,CSFShunt;ONSF,VisualFunction,Fulminant;RefractoryIIH,Surgical
procedures (CSF diversion, ONSF) are for imminent risk of visual loss
(fulminant IIH).,ExpertOpinion,No,NR,Defines indication for surgery
(fulminant vision loss).,10.1136/jnnp-2017-317440.pdf

Thakore_2016_RIMJ,Thakore,2016,R I Med
J,NarrativeReview,Adults,mild_visual_loss,Management,S01,TreatmentRecommendation,Acetazolamide;WeightLoss,VisualFunction,IIHTT;CAI,IIHTT
evaluated ACZ + weight loss vs placebo + weight loss
(WLO).,NR,Yes,IIHTT,Defines IIHTT arms.,2016-05-22-cont-thakore.pdf

Thakore_2016_RIMJ,Thakore,2016,R I Med
J,NarrativeReview,Adults,mild_visual_loss,Management,S02,PrognosisSummary,WeightLoss;Acetazolamide,Weight,IIHTT;Confounding,ACZ
group (6.96% mean weight loss) had \>double the weight loss of the WLO
group (3.20%).,NR,Yes,IIHTT,Highlights confounding weight loss in
IIHTT.,2016-05-22-cont-thakore.pdf

Thakore_2016_RIMJ,Thakore,2016,R I Med
J,NarrativeReview,Adults,mild_visual_loss,Management,S03,PrognosisSummary,Acetazolamide,VisualFunction,IIHTT;Interpretation,IIHTT
failed to demonstrate ACZ effectiveness at the \*targeted\* 6% weight
loss (WLO group failed to achieve it).,NR,Yes,IIHTT,Interprets IIHTT
primary outcome failure.,2016-05-22-cont-thakore.pdf

Thakore_2016_RIMJ,Thakore,2016,R I Med
J,NarrativeReview,Adults,mild_visual_loss,Management,S04,PrognosisSummary,WeightLoss;Acetazolamide,VisualFunction,IIHTT;Subgroup,\"At
3% weight loss (achieved by both groups), WLO had better PMD improvement
(1.61 dB) vs ACZ (0.94 dB).\",NR,Yes,IIHTT,Sub-analysis suggests weight
loss alone is effective at 3%.,2016-05-22-cont-thakore.pdf

Thakore_2016_RIMJ,Thakore,2016,R I Med
J,NarrativeReview,Adults,general_IIH,Management,S05,TreatmentRecommendation,WeightLoss,Papilledema,Threshold;Remission,\"6%
weight loss alone can result in resolution of papilledema and
IIH.\",NR,Yes,Johnson 1998; Johnson 1999,Defines 6% as a potential
remission threshold.,2016-05-22-cont-thakore.pdf

Thakore_2016_RIMJ,Thakore,2016,R I Med
J,NarrativeReview,Adults,general_IIH,Mechanisms,S06,Mechanism,Obesity,ICP,EndocrineMetabolic;Adipokines,\"Adipose-secreted
substances (retinol-binding protein, aromatase, cytokines, leptins) may
be involved in IIH.\",NR,No,NR,Links obesity to IIH via
metabolic/hormonal paths.,2016-05-22-cont-thakore.pdf

Thakore_2016_RIMJ,Thakore,2016,R I Med
J,NarrativeReview,Adults,general_IIH,Mechanisms,S07,Mechanism,VenousSinusStenosis,ICP,VenousOutflow;CSF_Resistance,\"Venous
sinus stenosis or microthrombosis as a primal cause of IIH\... is
uncertain.\",NR,No,NR,Questions VSS as primary cause vs.
effect.,2016-05-22-cont-thakore.pdf

Smith_2017_Headache,Smith,2017,Headache,NarrativeReview,Adults,mild_visual_loss,Management,S01,PrognosisSummary,Acetazolamide,VisualFunction,IIHTT;PMD,IIHTT:
ACZ group PMD improved 1.43 dB vs 0.71 dB in placebo
(p=0.050).,High,Yes,IIHTT (Wall 2014),Reports primary outcome (marginal
significance).,smith2017.pdf

Smith_2017_Headache,Smith,2017,Headache,NarrativeReview,Adults,mild_visual_loss,Management,S02,PrognosisSummary,Acetazolamide,Papilledema,IIHTT;FrisenGrade;OCT,ACZ
significantly improved papilledema grade (p\<0.001) and RNFL thickness
(p\<0.001) vs placebo.,High,Yes,IIHTT (Wall 2014),Reports strong effect
on papilledema/RNFL.,smith2017.pdf

Smith_2017_Headache,Smith,2017,Headache,NarrativeReview,Adults,mild_visual_loss,Management,S03,PrognosisSummary,Acetazolamide;WeightLoss,Weight,IIHTT;Confounding,ACZ
group lost significantly more weight (mean -7.50 kg) vs placebo (-3.45
kg) (p=0.002).,High,Yes,IIHTT (Wall 2014),Confirms weight loss
confounding in IIHTT.,smith2017.pdf

Smith_2017_Headache,Smith,2017,Headache,NarrativeReview,Adults,mild_visual_loss,Management,S04,PrognosisSummary,Acetazolamide,Headache,IIHTT;QoL,ACZ
group had greater improvement in headache disability (HIT-6)
(p=0.04).,High,Yes,IIHTT (Wall 2014),Shows ACZ benefit for headache
disability.,smith2017.pdf

Smith_2017_Headache,Smith,2017,Headache,NarrativeReview,Adults,mild_visual_loss,Management,S05,PrognosisSummary,Acetazolamide,ICP,IIHTT;CSFPressure,ACZ
reduced CSF pressure by 108 mm H2O (13.8%) vs 46 mm H2O (6.1%) in
placebo (p=0.01).,High,Yes,IIHTT (Wall 2014),Quantifies ICP reduction by
ACZ in IIHTT.,smith2017.pdf

Smith_2017_Headache,Smith,2017,Headache,NarrativeReview,Adults,mild_visual_loss,Management,S06,PrognosisSummary,Acetazolamide,Other,IIHTT;SideEffects,ACZ
group had higher rates of adverse events (paresthesia, dysgeusia,
fatigue).,High,Yes,IIHTT (ten Hove 2016),Notes high side-effect burden
of high-dose ACZ.,smith2017.pdf

Sinclair_2016_LancetNeurol,Sinclair,2016,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Mechanisms,S01,Mechanism,None,ICP,CSFProduction;CSF_Drainage;VenousPressure,Proposed
mechanisms: 1) CSF overproduction 2) reduced CSF drainage 3) raised
cerebral venous pressure.,NR,No,NR,Summarizes the three core pathophys
theories.,sinclair2016.pdf

Sinclair_2016_LancetNeurol,Sinclair,2016,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Mechanisms,S02,Mechanism,None,ICP,CSFProduction;ChoroidPlexus,Evidence
suggests IIH is \*not\* due to CSF hypersecretion.,NR,No,NR,Refutes the
CSF overproduction theory.,sinclair2016.pdf

Sinclair_2016_LancetNeurol,Sinclair,2016,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Mechanisms,S03,Mechanism,VenousSinusStenosis,ICP,VenousOutflow;CauseVsConsequence,\"VSS
is common, but unclear if cause or consequence of raised
ICP.\",NR,No,NR,Highlights the VSS \'chicken-or-egg\'
debate.,sinclair2016.pdf

Sinclair_2016_LancetNeurol,Sinclair,2016,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Mechanisms,S04,Mechanism,AndrogenExcess,ICP,EndocrineMetabolic;Testosterone,Evidence
links IIH to androgen excess (higher testosterone).,NR,No,NR,Identifies
androgen excess as a key metabolic link.,sinclair2016.pdf

Sinclair_2016_LancetNeurol,Sinclair,2016,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Mechanisms,S05,Mechanism,Glucocorticoids,ICP,EndocrineMetabolic;11beta-HSD1;Obesity,\"Adipose
tissue 11β-HSD1 activity is increased in IIH, locally generating active
cortisol.\",NR,No,NR,Links IIH to 11β-HSD1 and
cortisol.,sinclair2016.pdf

Sinclair_2016_LancetNeurol,Sinclair,2016,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Management,S06,TreatmentRecommendation,Acetazolamide,ICP,CAI;CSFProduction,Acetazolamide
(carbonic anhydrase inhibitor) is the most common medical
treatment.,NR,No,NR,Establishes ACZ as standard first-line
drug.,sinclair2016.pdf

Sinclair_2016_LancetNeurol,Sinclair,2016,Lancet
Neurol,NarrativeReview,Adults,mild_visual_loss,Management,S07,TreatmentRecommendation,Acetazolamide;WeightLoss,VisualFunction,IIHTT;CAI,IIHTT
showed ACZ (up to 4g/day) + diet modestly improved vision vs diet alone
in mild loss.,High,Yes,IIHTT (Wall 2014),Summarizes IIHTT primary
outcome.,sinclair2016.pdf

Sinclair_2016_LancetNeurol,Sinclair,2016,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Management,S08,TreatmentRecommendation,Topiramate,ICP;Weight,CAI;WeightLoss,\"Topiramate
inhibits carbonic anhydrase and promotes weight loss; used as
alternative to ACZ.\",Low,No,NR,Positions TPM as a 2nd-line CAI/weight
loss agent.,sinclair2016.pdf

Sinclair_2016_LancetNeurol,Sinclair,2016,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Management,S09,TreatmentRecommendation,WeightLoss,ICP;Papilledema,Threshold;Remission,\"Weight
loss (6-10%) is associated with IIH resolution.\",NR,Yes,Johnson 1998;
Sinclair 2010,Defines quantitative weight loss target for
remission.,sinclair2016.pdf

Sinclair_2016_LancetNeurol,Sinclair,2016,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Management,S10,SurgicalRecommendation,BariatricSurgery,ICP;Weight,Remission,\"Bariatric
surgery is effective for IIH remission, but evidence is low
quality.\",Low,No,NR,Positions bariatric surgery as a weight loss
intervention.,sinclair2016.pdf

Sinclair_2016_LancetNeurol,Sinclair,2016,Lancet
Neurol,NarrativeReview,Adults,fulminant,Management,S11,SurgicalRecommendation,CSFShunt;ONSF;VenousSinusStenting,VisualFunction,Fulminant;RefractoryIIH,\"Surgery
(CSF shunting, ONSF, VSS) is for refractory or fulminant
IIH.\",NR,No,NR,Defines criteria for surgical
intervention.,sinclair2016.pdf

Oernbo_2023_BasicClinPharmacolToxicol,Oernbo,2023,Basic Clin Pharmacol
Toxicol,NarrativeReview,NotApplicable,general_IIH,Mechanisms,S01,PreclinicalMechanism,GLP1RA,CSF_Production;ICP,ChoroidPlexus;NaK-ATPase;GLP1R,\"GLP-1R
agonists inhibit choroid plexus Na+/K+-ATPase activity, reducing CSF
secretion/ICP.\",NR,Yes,Botfield 2017; Mitchell 2023,Defines mechanism
of GLP-1RA on CSF/ICP.,PIIS2589004222015814.pdf

Oernbo_2023_BasicClinPharmacolToxicol,Oernbo,2023,Basic Clin Pharmacol
Toxicol,NarrativeReview,Adults,general_IIH,Management,S02,TreatmentRecommendation,GLP1RA,ICP,IIH;GLP1R,Exenatide
(a GLP-1R agonist) reduced ICP in IIH patients in a randomized
trial.,High,Yes,Mitchell 2023,Cites human trial data for GLP-1RA in
IIH.,PIIS2589004222015814.pdf

Oernbo_2023_BasicClinPharmacolToxicol,Oernbo,2023,Basic Clin Pharmacol
Toxicol,NarrativeReview,NotApplicable,general_IIH,Mechanisms,S03,Mechanism,None,CSF_Production,ChoroidPlexus;NaK-ATPase;NKCC1,\"CSF
secretion is driven by CP ion transporters (NKA, NKCC1,
HCO3-).\",NR,No,NR,Standard model of CSF
production.,PIIS2589004222015814.pdf

Oernbo_2023_BasicClinPharmacolToxicol,Oernbo,2023,Basic Clin Pharmacol
Toxicol,NarrativeReview,NotApplicable,general_IIH,Mechanisms,S04,Mechanism,Acetazolamide;Topiramate,CSF_Production,CAI;ChoroidPlexus;HCO3-,\"ACZ
and TPM inhibit carbonic anhydrase, reducing HCO3- available for
transport.\",NR,No,NR,Defines CAI mechanism of
action.,PIIS2589004222015814.pdf

Oernbo_2023_BasicClinPharmacolToxicol,Oernbo,2023,Basic Clin Pharmacol
Toxicol,NarrativeReview,NotApplicable,general_IIH,Preclinical,S05,PreclinicalMechanism,Topiramate;Acetazolamide,ICP,CAI;Potency,\"Preclinical:
TPM is more potent than ACZ at lowering ICP in rats.\",NR,Yes,Westgate
2023,Compares potency of ACZ and TPM in vivo.,PIIS2589004222015814.pdf

Oernbo_2023_BasicClinPharmacolToxicol,Oernbo,2023,Basic Clin Pharmacol
Toxicol,NarrativeReview,NotApplicable,general_IIH,Preclinical,S06,PreclinicalMechanism,GLP1RA,ICP,GLP1R;ChoroidPlexus,GLP-1R
agonists (exenatide, liraglutide) reduce ICP in preclinical
models.,NR,Yes,Botfield 2017; Hakon 2015,Establishes preclinical
efficacy of GLP-1RAs.,PIIS2589004222015814.pdf

Oernbo_2023_BasicClinPharmacolToxicol,Oernbo,2023,Basic Clin Pharmacol
Toxicol,NarrativeReview,NotApplicable,general_IIH,Mechanisms,S07,Mechanism,GLP1RA;Acetazolamide,TransporterActivity,NaK-ATPase;CAI;GLP1R,\"GLP-1RAs
reduce Na+/K+-ATPase activity, unlike acetazolamide which does
not.\",NR,Yes,Westgate 2023,Contrasts mechanisms of GLP-1RA vs
ACZ.,PIIS2589004222015814.pdf

Ball_2006_LancetNeurol,Ball,2006,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Mechanisms,S01,Mechanism,None,ICP,CSFProduction;CSF_Drainage,\"Pathophysiology
unknown; theories include CSF overproduction or impaired
absorption.\",NR,No,NR,Standard pathophysiological
theories.,PIIS014067369712390X.pdf

Ball_2006_LancetNeurol,Ball,2006,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Management,S02,RiskFactor,Obesity;WeightLoss,Remission,DiseaseModification,\"\>90%
of patients are obese; weight loss can lead to
remission.\",NR,No,NR,Links obesity risk and weight loss
treatment.,PIIS014067369712390X.pdf

Ball_2006_LancetNeurol,Ball,2006,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Management,S03,TreatmentRecommendation,Acetazolamide,ICP;CSF_Production,CAI,\"ACZ
is mainstay of medical treatment; reduces CSF
production.\",NR,No,NR,Establishes ACZ as standard of
care.,PIIS014067369712390X.pdf

Ball_2006_LancetNeurol,Ball,2006,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Management,S04,DosingRecommendation,Acetazolamide,ICP,CAI;Dosing,\"Typical
ACZ doses are 1-2 g daily, but up to 4 g/day may be
needed.\",NR,No,NR,Provides typical and max dosing for
ACZ.,PIIS014067369712390X.pdf

Ball_2006_LancetNeurol,Ball,2006,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Management,S05,TreatmentRecommendation,Topiramate,ICP;Headache,CAI;Migraine,\"Topiramate
is an alternative; inhibits carbonic anhydrase and is used for
migraine.\",NR,No,NR,Positions TPM as an alternative
CAI.,PIIS014067369712390X.pdf

Ball_2006_LancetNeurol,Ball,2006,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Management,S06,TreatmentRecommendation,Furosemide,ICP,Diuretic,\"Loop
diuretics (furosemide) are used, but evidence for their efficacy is
poor.\",NR,No,NR,Questions efficacy of
furosemide.,PIIS014067369712390X.pdf

Ball_2006_LancetNeurol,Ball,2006,Lancet
Neurol,NarrativeReview,Adults,general_IIH,Management,S07,TreatmentRecommendation,WeightLoss,Papilledema,Threshold;Remission,\"Weight
loss of 6% or more is associated with resolution of
papilloedema.\",NR,Yes,Johnson 1998,Defines 6% weight loss
threshold.,PIIS014067369712390X.pdf

K_2021_JNeuroophthalmol,K.,2021,J
Neuroophthalmol,NarrativeReview,Adults,general_IIH,Management,S01,TreatmentRecommendation,WeightLoss,Remission,DiseaseModification;Obesity,\"Weight
loss is the only disease-modifying treatment that can lead to remission
of IIH.\",NR,No,NR,Re-confirms weight loss as primary disease
modifier.,Weight_reduction_for_a_better_visual_outcome_in_id.pdf

K_2021_JNeuroophthalmol,K.,2021,J
Neuroophthalmol,NarrativeReview,Adults,general_IIH,Management,S02,TreatmentRecommendation,WeightLoss,Papilledema;Remission,Threshold,\"Weight
loss of 6-10% of total body weight is associated with resolution of
papilledema and remission.\",NR,Yes,Johnson 1998; Sinclair 2010,Defines
6-10% weight loss
target.,Weight_reduction_for_a_better_visual_outcome_in_id.pdf

K_2021_JNeuroophthalmol,K.,2021,J
Neuroophthalmol,NarrativeReview,Adults,mild_visual_loss,Management,S03,PrognosisSummary,Acetazolamide;WeightLoss,VisualFunction,IIHTT,\"IIHTT
demonstrated that ACZ + diet resulted in greater improvement in visual
fields than diet alone.\",High,Yes,IIHTT (Wall 2014),Cites IIHTT primary
outcome.,Weight_reduction_for_a_better_visual_outcome_in_id.pdf

K_2021_JNeuroophthalmol,K.,2021,J
Neuroophthalmol,NarrativeReview,Adults,mild_visual_loss,Management,S04,PrognosisSummary,Acetazolamide;WeightLoss,Weight,IIHTT;Confounding,\"IIHTT
ACZ group lost significantly more weight (7.5 kg) than the placebo group
(3.45 kg).\",High,Yes,IIHTT (Wall 2014),Notes the weight loss confound
in IIHTT.,Weight_reduction_for_a_better_visual_outcome_in_id.pdf

K_2021_JNeuroophthalmol,K.,2021,J
Neuroophthalmol,NarrativeReview,Adults,general_IIH,Management,S05,SurgicalRecommendation,BariatricSurgery,Remission,WeightLoss;Obesity,\"Bariatric
surgery is a highly effective treatment for IIH, resulting in remission
in \>90% of cases.\",Low,No,NR,Strong recommendation for bariatrics for
weight loss.,Weight_reduction_for_a_better_visual_outcome_in_id.pdf

K_2021_JNeuroophthalmol,K.,2021,J
Neuroophthalmol,NarrativeReview,Adults,general_IIH,Prognosis,S06,PrognosisSummary,BariatricSurgery;CSFShunt,Headache,WeightLoss,\"Bariatric
surgery is superior to CSF shunting for long-term headache
resolution.\",Low,No,NR,Compares bariatrics to shunting for
headache.,Weight_reduction_for_a_better_visual_outcome_in_id.pdf

A_2024_BrainSci,A.,2024,Brain
Sci,NarrativeReview,Adults,general_IIH,Mechanisms,S01,Mechanism,None,ICP;Papilledema,Diagnosis;CSFPressure,\"IIH
characterized by elevated ICP (\>=250 mmH2O) without secondary causes,
causing papilledema.\",NR,Yes,Wall 2014,Defines diagnostic ICP
threshold.,brainsci-15-01064-v2.pdf

A_2024_BrainSci,A.,2024,Brain
Sci,NarrativeReview,Adults,general_IIH,Management,S02,TreatmentRecommendation,None,VisualFunction;Headache,Goals,\"Treatment
aims to protect vision and manage headache episodes.\",NR,No,NR,Defines
goals of therapy.,brainsci-15-01064-v2.pdf

A_2024_BrainSci,A.,2024,Brain
Sci,NarrativeReview,Adults,general_IIH,Management,S03,TreatmentRecommendation,Acetazolamide,ICP,CAI;FirstLine,\"Acetazolamide
(carbonic anhydrase inhibitor) is first-line medical
therapy.\",NR,No,NR,Confirms ACZ as first-line.,brainsci-15-01064-v2.pdf

A_2024_BrainSci,A.,2024,Brain
Sci,NarrativeReview,Adults,general_IIH,Mechanisms,S04,Mechanism,Acetazolamide,CSF_Production,CAI;ChoroidPlexus,\"ACZ
reduces CSF production by inhibiting carbonic anhydrase in the choroid
plexus.\",NR,No,NR,Defines ACZ mechanism.,brainsci-15-01064-v2.pdf

A_2024_BrainSci,A.,2024,Brain
Sci,NarrativeReview,Adults,general_IIH,Management,S05,TreatmentRecommendation,WeightLoss,ICP,DiseaseModification;Obesity,\"Weight
management is a primary approach, as weight loss lowers
ICP.\",NR,No,NR,Emphasizes weight loss
importance.,brainsci-15-01064-v2.pdf

A_2024_BrainSci,A.,2024,Brain
Sci,NarrativeReview,Adults,general_IIH,Management,S06,TreatmentRecommendation,Topiramate,ICP;Weight;Headache,CAI;Migraine,\"Topiramate
is an alternative; also a carbonic anhydrase inhibitor, and helps with
weight loss and migraine.\",NR,No,NR,Defines role of
TPM.,brainsci-15-01064-v2.pdf

A_2024_BrainSci,A.,2024,Brain
Sci,NarrativeReview,Adults,general_IIH,Mechanisms,S07,Mechanism,GLP1RA,ICP;CSF_Production,GLP1R;ChoroidPlexus;NaK-ATPase,\"GLP-1
receptor agonists (e.g., Exenatide) reduce ICP by reducing CSF
production via choroid plexus Na+/K+-ATPase.\",NR,Yes,Botfield 2017;
Mitchell 2023,Describes GLP-1RA mechanism.,brainsci-15-01064-v2.pdf

A_2024_BrainSci,A.,2024,Brain
Sci,NarrativeReview,Adults,general_IIH,Mechanisms,S08,Mechanism,None,ICP,EndocrineMetabolic,\"IIH
is increasingly recognized as a systemic metabolic disorder, not just a
CNS disorder.\",NR,No,NR,Frames IIH as metabolic
disease.,brainsci-15-01064-v2.pdf

A_2024_BrainSci,A.,2024,Brain
Sci,NarrativeReview,Adults,general_IIH,Mechanisms,S09,Mechanism,AndrogenExcess;Leptin,ICP,EndocrineMetabolic,\"Distinct
androgen excess and hyperleptinemia have been noted in
IIH.\",NR,Yes,O\'Reilly 2019; Westgate 2021,Links IIH to specific
hormonal dysfunction.,brainsci-15-01064-v2.pdf

A_2024_BrainSci,A.,2024,Brain
Sci,NarrativeReview,Adults,general_IIH,Mechanisms,S10,Mechanism,None,CSF_Drainage,Glymphatic;AQP4,\"Impaired
glymphatic drainage may contribute to IIH
pathogenesis.\",NR,No,NR,Identifies glymphatic dysfunction as a
mechanism.,brainsci-15-01064-v2.pdf

A_2024_BrainSci,A.,2024,Brain
Sci,NarrativeReview,Adults,general_IIH,Mechanisms,S11,ImagingMarker,VenousSinusStenosis,ICP,VenousOutflow,\"CVSS
is present in up to 90% of IIH patients.\",NR,No,NR,Notes high
prevalence of VSS.,brainsci-15-01064-v2.pdf

A_2024_BrainSci,A.,2024,Brain
Sci,NarrativeReview,Adults,general_IIH,Imaging,S12,ImagingMarker,Papilledema,VisualFunction,Diagnosis,\"Papilledema
is a critical diagnostic sign of IIH.\",NR,Yes,Wall 2014,Emphasizes role
of papilledema.,brainsci-15-01064-v2.pdf

S_2025_BrainSci,S.,2025,Brain
Sci,NarrativeReview,Adults,general_IIH,Mechanisms,S01,Mechanism,None,ICP;Papilledema,Diagnosis,\"IIH
is characterized by elevated ICP (\>=25 cmH2O) leading to
papilledema.\",NR,Yes,Wall 2014,Links ICP threshold to
papilledema.,brainsci-15-00527.pdf

S_2025_BrainSci,S.,2025,Brain
Sci,NarrativeReview,Adults,general_IIH,Management,S02,TreatmentRecommendation,Acetazolamide,ICP,CAI;FirstLine,\"Medical
treatment aims to lower ICP, with acetazolamide (a CAI) being the
first-line therapy.\",NR,No,NR,Confirms ACZ as
first-line.,brainsci-15-00527.pdf

S_2025_BrainSci,S.,2025,Brain
Sci,NarrativeReview,Adults,general_IIH,Mechanisms,S03,Mechanism,Acetazolamide,CSF_Production,CAI;ChoroidPlexus,\"Acetazolamide
reduces CSF production by 46-57%.\",NR,No,NR,Quantifies ACZ effect on
CSF production.,brainsci-15-00527.pdf

S_2025_BrainSci,S.,2025,Brain
Sci,NarrativeReview,Adults,general_IIH,Management,S04,TreatmentRecommendation,Topiramate,ICP;Weight;Headache,CAI;MultiMechanism,\"Topiramate
is also used, inhibiting CA, blocking sodium channels, and promoting
weight loss.\",NR,No,NR,Describes Topiramate\'s multiple
mechanisms.,brainsci-15-00527.pdf

S_2025_BrainSci,S.,2025,Brain
Sci,NarrativeReview,Adults,general_IIH,Imaging,S05,MonitoringRecommendation,Papilledema,VisualFunction,FrisenGrade;Monitoring,\"Papilledema
severity (e.g., Frisen grade) is a key marker for monitoring treatment
response.\",NR,No,NR,Defines papilledema as monitoring
tool.,brainsci-15-00527.pdf

S_2025_BrainSci,S.,2025,Brain
Sci,NarrativeReview,Adults,general_IIH,Imaging,S06,MonitoringRecommendation,OCT,Papilledema;Prognosis,RNFL;Monitoring,\"OCT
is a quantitative, non-invasive tool to measure peripapillary RNFL
thickness, monitoring edema and atrophy.\",NR,No,NR,Defines OCT\'s
role.,brainsci-15-00527.pdf

S_2025_BrainSci,S.,2025,Brain
Sci,NarrativeReview,Adults,general_IIH,Imaging,S07,MonitoringRecommendation,VisualField,VisualFunction,PMD;Monitoring,\"Automated
perimetry (visual fields) is crucial for monitoring functional vision
loss.\",NR,No,NR,Defines VF\'s
role.,brainsci-1S_2025_BrainSci,S.,2025,Brain
Sci,NarrativeReview,Adults,mild_visual_loss,Management,S08,PrognosisSummary,Acetazolamide;WeightLoss,VisualFunction,IIHTT;PMD,\"IIHTT
showed ACZ + diet improved visual fields (PMD) more than diet alone in
mild IIH.\",High,Yes,IIHTT (Wall 2014),Cites IIHTT primary
outcome.,brainsci-15-00527.pdf

F_2022_FrontOphthalmol,F.,2022,Front
Ophthalmol,NarrativeReview,Adults,general_IIH,Imaging,S01,MonitoringRecommendation,OCTA,Papilledema,Vasculature;Monitoring,OCT-Angiography
(OCTA) is an emerging tool to visualize peripapillary
vasculature.,NR,No,NR,Introduces OCTA as a new
tool.,fopht-02-1042529.pdf

F_2022_FrontOphthalmol,F.,2022,Front
Ophthalmol,NarrativeReview,Adults,general_IIH,Imaging,S02,ImagingMarker,OCTA,Papilledema,Vasculature;VesselDensity,OCTA
studies show increased peripapillary vessel density (VD) in acute
papilledema.,NR,No,NR,OCTA finding in acute stage.,fopht-02-1042529.pdf

F_2022_FrontOphthalmol,F.,2022,Front
Ophthalmol,NarrativeReview,Adults,general_IIH,Imaging,S03,ImagingMarker,OCTA,Papilledema,Vasculature;VesselDensity;Atrophy,OCTA
shows decreased peripapillary VD in chronic/atrophic
papilledema.,NR,No,NR,OCTA finding in chronic
stage.,fopht-02-1042529.pdf

F_2022_FrontOphthalmol,F.,2022,Front
Ophthalmol,NarrativeReview,Adults,general_IIH,Imaging,S04,ImagingMarker,OCTA,Prognosis,Vasculature;SubclinicalDamage,OCTA
may detect subclinical vascular changes before RNFL loss, potentially
predicting visual outcome.,NR,No,NR,Highlights prognostic potential of
OCTA.,fopht-02-1042529.pdf

Agarwa_2015_MSCNR,Agarwa,2015,MSCNR,CaseSeriesReview,Adults,general_IIH,CSFLeak,S01,Mechanism,CSFRhinorrhea,ICP,CSFLeak,Spontaneous
CSF rhinorrhea (S-CSFR) is an uncommon presentation of
IIH.,NR,No,NR,Links IIH to CSF leaks.,NiveditaAgarwalMSCNR.doc.pdf

Agarwa_2015_MSCNR,Agarwa,2015,MSCNR,CaseSeriesReview,Adults,general_IIH,CSFLeak,S02,Mechanism,CSFRhinorrhea,ICP,CSFLeak;BonyErosion,\"Elevated
ICP in IIH can cause bony erosion of the skull base, leading to
S-CSFR.\",NR,No,NR,Mechanism of IIH-induced CSF
leak.,NiveditaAgarwalMSCNR.doc.pdf

Agarwa_2015_MSCNR,Agarwa,2015,MSCNR,CaseSeriesReview,Adults,general_IIH,CSFLeak,S03,TreatmentRecommendation,Acetazolamide;WeightLoss;Surgery,CSFLeak;ICP,ManagementAlgorithm,\"Management
of IIH-CSFR: ICP lowering (weight loss, ACZ) and surgical
repair.\",NR,No,NR,Treatment approach for IIH-CSF
leaks.,NiveditaAgarwalMSCNR.doc.pdf

Kupersmith_1981_JNeurosurg,Kupersmith,1981,J
Neurosurg,OriginalCohort,Mixed,general_IIH,Imaging,S01,ImagingMarker,VisualField,VisualFunction,PMD,\"Visual
loss in pseudotumor cerebri (IIH) was predominantly visual field defects
(constriction, blind spot).\",NR,No,NR,Characterizes visual loss
type.,j-neurosurg-article-p430.pdf

Kupersmith_1981_JNeurosurg,Kupersmith,1981,J
Neurosurg,OriginalCohort,Mixed,general_IIH,Prognosis,S02,PrognosisSummary,Papilledema,VisualFunction,Atrophy;Timeline,\"Optic
disc swelling (papilledema) often resolved (average 3.5 months) but
optic atrophy occurred in 21% of IIH group.\",NR,No,NR,Describes
outcome/timeline of papilledema.,j-neurosurg-article-p430.pdf

Kupersmith_1981_JNeurosurg,Kupersmith,1981,J
Neurosurg,OriginalCohort,Mixed,general_IIH,Prognosis,S03,PrognosisSummary,None,VisualFunction,Prognosis,\"Visual
outcome in pseudotumor cerebri (IIH) was generally good, but 10% had
severe visual loss.\",NR,No,NR,Quantifies risk of severe visual
loss.,j-neurosurg-article-p430.pdf

Eftekhari_2019_FluidsBarriersCNS,Eftekhari,2019,Fluids Barriers
CNS,PreclinicalReview,NotApplicable,general_IIH,Preclinical,S01,PreclinicalMechanism,None,ICP,PreclinicalModel;Monitoring,\"ICP
monitoring in rodents is challenging; long-term methods are needed but
limited.\",NR,No,NR,Highlights preclinical methods
gap.,12987_2019_Article_155.pdf

Eftekhari_2019_FluidsBarriersCNS,Eftekhari,2019,Fluids Barriers
CNS,PreclinicalReview,NotApplicable,general_IIH,Preclinical,S02,PreclinicalMechanism,Obesity,ICP,PreclinicalModel;ZuckerRat,\"Obese
Zucker rat model mimics some IIH aspects (raised ICP).\",NR,Yes,Uldall
2017,Describes an IIH animal model.,12987_2019_Article_155.pdf

Eftekhari_2019_FluidsBarriersCNS,Eftekhari,2019,Fluids Barriers
CNS,PreclinicalReview,NotApplicable,general_IIH,Preclinical,S03,PreclinicalMechanism,Acetazolamide,ICP,CAI;PreclinicalModel,\"Preclinical
studies suggest acetazolamide (ACZ) may have limited or no effect on
ICP.\",NR,Yes,Scotton 2018,Questions ACZ efficacy in preclinical
models.,12987_2019_Article_155.pdf

Eftekhari_2019_FluidsBarriersCNS,Eftekhari,2019,Fluids Barriers
CNS,PreclinicalReview,NotApplicable,general_IIH,Preclinical,S04,PreclinicalMechanism,Topiramate;GLP1RA,ICP,PreclinicalModel,\"Topiramate
and GLP-1R agonists can lower ICP in healthy rodents.\",NR,Yes,Scotton
2018; Botfield 2017,Identifies alternative preclinical
targets.,12987_2019_Article_155.pdf

Eftekhari_2019_FluidsBarriersCNS,Eftekhari,2019,Fluids Barriers
CNS,PreclinicalReview,NotApplicable,general_IIH,Mechanisms,S05,PreclinicalMechanism,None,CSF_Production,ChoroidPlexus;NaK-ATPase;NKCC1,\"Majority
of CSF is generated via choroid plexus (CP) via ion transporters (Na+/K+
ATPase, NKCC1).\",NR,No,NR,Defines standard CSF secretion
mechanism.,12987_2019_Article_155.pdf

Eftekhari_2019_FluidsBarriersCNS,Eftekhari,2019,Fluids Barriers
CNS,PreclinicalReview,NotApplicable,general_IIH,Mechanisms,S06,PreclinicalMechanism,None,CSF_Drainage,Glymphatic;Lymphatic;AG,\"CSF
drainage occurs via arachnoid granulations (AG), glymphatics
(AQP4-dependent), and lymphatics (nasal, dural).\",NR,No,NR,Summarizes
CSF drainage pathways.,12987_2019_Article_155.pdf

Eftekhari_2019_FluidsBarriersCNS,Eftekhari,2019,Fluids Barriers
CNS,PreclinicalReview,Adults,general_IIH,Mechanisms,S07,Mechanism,None,ICP,Compliance;ICP_Waveform,\"IIH
patients have larger ICP wave amplitudes, indicating reduced parenchymal
compliance.\",NR,Yes,Eide 2011,Links IIH to ICP
pulsatility/compliance.,12987_2019_Article_155.pdf

Eftekhari_2019_FluidsBarriersCNS,Eftekhari,2019,Fluids Barriers
CNS,PreclinicalReview,NotApplicable,general_IIH,Preclinical,S08,PreclinicalMechanism,Acetazolamide,ICP;TransporterActivity,CAI;AQP1;NaK-ATPase,\"High-dose
ACZ (200mg i.p.) lowered ICP in healthy rats; increased membrane
AQP1/NKA.\",NR,Yes,Uldall 2017,Describes high-dose ACZ
effect.,12987_2019_Article_155.pdf

Eftekhari_2019_FluidsBarriersCNS,Eftekhari,2019,Fluids Barriers
CNS,PreclinicalReview,NotApplicable,general_IIH,Preclinical,S09,PreclinicalMechanism,Acetazolamide,ICP,CAI;Dosing;PreclinicalModel,\"Clinically
relevant ACZ doses (oral/s.c.) did not significantly lower ICP in
rats.\",NR,Yes,Scotton 2018,Contradicts high-dose ACZ
effect.,12987_2019_Article_155.pdf

Eftekhari_2019_FluidsBarriersCNS,Eftekhari,2019,Fluids Barriers
CNS,PreclinicalReview,NotApplicable,general_IIH,Preclinical,S10,PreclinicalMechanism,Topiramate,ICP,CAI;Dosing;PreclinicalModel,\"Topiramate
(clinical doses) significantly lowered ICP (32% and 21%) in healthy
rats.\",NR,Yes,Scotton 2018,Shows preclinical efficacy of
TPM.,12987_2019_Article_155.pdf

Eftekhari_2019_FluidsBarriersCNS,Eftekhari,2019,Fluids Barriers
CNS,PreclinicalReview,NotApplicable,general_IIH,Preclinical,S11,PreclinicalMechanism,Furosemide;Amiloride,ICP,PreclinicalModel,\"Furosemide
and amiloride did not change ICP in healthy rats.\",NR,Yes,Scotton
2018,Questions efficacy of other diuretics.,12987_2019_Article_155.pdf

Eftekhari_2019_FluidsBarriersCNS,Eftekhari,2019,Fluids Barriers
CNS,PreclinicalReview,NotApplicable,general_IIH,Preclinical,S12,PreclinicalMechanism,Octreotide,ICP,PreclinicalModel,\"A
single dose of octreotide had no effect on ICP in rats.\",NR,Yes,Scotton
2018,Questions octreotide efficacy.,12987_2019_Article_155.pdf

Eftekhari_2019_FluidsBarriersCNS,Eftekhari,2019,Fluids Barriers
CNS,PreclinicalReview,NotApplicable,general_IIH,Preclinical,S13,PreclinicalMechanism,GLP1RA,ICP;CSF_Production,GLP1R;NaK-ATPase,\"Exendin-4
(GLP-1RA) reduced ICP in healthy and hydrocephalic rats by inhibiting
Na+/K+-ATPase.\",NR,Yes,Botfield 2017,Confirms GLP-1RA preclinical
mechanism.,12987_2019_Article_155.pdf

B_2011_JNeurol,Ball,2011,J
Neurol,OriginalCohort,Adults,general_IIH,Management,S01,TreatmentRecommendation,Acetazolamide;WeightLoss,VisualFunction,RCT;CAI,\"RCT:
acetazolamide (up to 4g/day) + diet vs. placebo +
diet.\",High,No,NR,Defines study
arms.,visual-outcome-of-patients-with-.pdf

B_2011_JNeurol,Ball,2011,J
Neurol,OriginalCohort,Adults,general_IIH,Prognosis,S02,PrognosisSummary,Acetazolamide,VisualFunction,RCT;VisualAcuity,No
significant difference found in primary visual outcome (logMAR visual
acuity) at 12 months.,High,No,NR,Reports negative primary outcome
(visual acuity).,visual-outcome-of-patients-with-.pdf

B_2011_JNeurol,Ball,2011,J
Neurol,OriginalCohort,Adults,general_IIH,Prognosis,S03,PrognosisSummary,Acetazolamide;WeightLoss,Headache;Papilledema;QoL,RCT,\"Significant
improvements in headache, papilledema, and QoL in both groups (no
difference between groups).\",High,No,NR,Shows no difference in
secondary outcomes.,visual-outcome-of-patients-with-.pdf

B_2011_JNeurol,Ball,2011,J
Neurol,OriginalCohort,Adults,general_IIH,Prognosis,S04,PrognosisSummary,Acetazolamide,Other,RCT;SideEffects,\"48%
of participants in the ACZ group withdrew (vs 20% placebo), mainly due
to adverse effects.\",High,No,NR,Highlights very high side-effect
burden/intolerance.,visual-outcome-of-patients-with-.pdf

B_2011_JNeurol,Ball,2011,J
Neurol,OriginalCohort,Adults,general_IIH,Prognosis,S05,PrognosisSummary,Acetazolamide,VisualFunction,RCT,Concludes
insufficient evidence to support ACZ use in IIH.,High,No,NR,Study
conclusion based on lack of
efficacy/tolerability.,visual-outcome-of-patients-with-.pdf

Solár_2020_FluidsBarriersCNS,Solár,2020,Fluids Barriers
CNS,NarrativeReview,Mixed,general_IIH,Mechanisms,S01,Mechanism,None,CSF_Production,ChoroidPlexus;BloodCSFBarrier,Choroid
plexus (CP) forms the blood-CSF (B-CSF) barrier and is crucial for brain
homeostasis.,NR,No,NR,Defines CP role.,12987_2020_00196-2.pdf

Solár_2020_FluidsBarriersCNS,Solár,2020,Fluids Barriers
CNS,NarrativeReview,Mixed,general_IIH,Mechanisms,S02,Mechanism,None,Other,ChoroidPlexus;Neurodegeneration,\"CP
is involved in pathophysiology of neurodegenerative (Alzheimer\'s) and
autoimmune (MS) diseases.\",NR,No,NR,Links CP to other CNS
diseases.,12987_2020_00196-2.pdf

Solár_2020_FluidsBarriersCNS,Solár,2020,Fluids Barriers
CNS,NarrativeReview,Mixed,general_IIH,Mechanisms,S03,Mechanism,None,Other,ChoroidPlexus;Stroke;TBI,\"CP
is important for restoring homeostasis after stroke and
trauma.\",NR,No,NR,Links CP to injury response.,12987_2020_00196-2.pdf

Solár_2020_FluidsBarriersCNS,Solár,2020,Fluids Barriers
CNS,NarrativeReview,Mixed,general_IIH,Mechanisms,S04,Mechanism,None,CSF_Production,ChoroidPlexus,\"Primary
function of CP epithelial cells is CSF secretion; may produce \>50% of
total CSF.\",NR,No,NR,Quantifies CP contribution to CSF
production.,12987_2020_00196-2.pdf

Solár_2020_FluidsBarriersCNS,Solár,2020,Fluids Barriers
CNS,NarrativeReview,Mixed,general_IIH,Mechanisms,S05,Mechanism,None,CSF_Production,IonTransport;ChoroidPlexus,\"CSF
formation depends mainly on Na+, K+, Cl-, HCO3- and H2O
transport.\",NR,No,NR,Lists key ions in CSF
secretion.,12987_2020_00196-2.pdf

Solár_2020_FluidsBarriersCNS,Solár,2020,Fluids Barriers
CNS,NarrativeReview,Mixed,general_IIH,Mechanisms,S06,Mechanism,None,CSF_Production,ChoroidPlexus;IonTransport;Polarity,\"Apical
transporters include Na+/K+-ATPase and NKCC1; Basolateral include HCO3-
transporters (NBCn1, NCBE, AE2).\",NR,No,NR,Details transporter
polarity.,12987_2020_00196-2.pdf

Solár_2020_FluidsBarriersCNS,Solár,2020,Fluids Barriers
CNS,NarrativeReview,Mixed,general_IIH,Mechanisms,S07,Mechanism,NKCC1,CSF_Production,ChoroidPlexus;WaterTransport,\"Apical
NKCC1 may contribute as much as half of CSF production via ion-mediated
water cotransport.\",NR,Yes,Steffensen 2018,Quantifies NKCC1
role.,12987_2020_00196-2.pdf

Solár_2020_FluidsBarriersCNS,Solár,2020,Fluids Barriers
CNS,NarrativeReview,Mixed,general_IIH,Mechanisms,S08,Mechanism,AQP1,CSF_Production,ChoroidPlexus;WaterTransport,\"AQP1
is highly expressed apically and contributes to 20-25% of the CSF
production.\",NR,Yes,Oshio 2005,Quantifies AQP1
role.,12987_2020_00196-2.pdf

Solár_2020_FluidsBarriersCNS,Solár,2020,Fluids Barriers
CNS,NarrativeReview,Mixed,general_IIH,Preclinical,S09,PreclinicalMechanism,NKCC1,CSF_Production,ChoroidPlexus;Inflammation;TLR4;SPAK,\"In
IVH models, TLR4 activation in CP leads to CSF hypersecretion via SPAK
and NKCC1.\",NR,Yes,Karimy 2017,Links inflammation (TLR4) to
NKCC1-driven CSF hypersecretion.,12987_2020_00196-2.pdf

Solár_2020_FluidsBarriersCNS,Solár,2020,Fluids Barriers
CNS,NarrativeReview,Mixed,general_IIH,Mechanisms,S10,Mechanism,NKCC1,CSF_Production,Hydrocephalus;ChoroidPlexus,\"Upregulation
of NKCC1 may cause post-hemorrhagic hydrocephalus.\",NR,No,NR,Links
NKCC1 to hydrocephalus.,12987_2020_00196-2.pdf
